brick layer850

Pembrolizumab (Keytruda) induced an overall response rate (ORR) of 33% in patients with extensive-stage small cell lung cancer (SCLC), according to findings from the open-label, phase Ib KEYNOTE-028 trial published in the Journal of Clinical Oncology.

“This study is, to our knowledge, the first report to evaluate the immune checkpoint inhibitor pembrolizumab in patients with heavily pretreated (87.5% with 2 or more lines of prior therapy; 37.5% with 3 or more) extensive-stage SCLC,” first author Patrick A. Ott, MD, PhD, clinical director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, and coinvestigators wrote. “Pembrolizumab showed clinically meaningful antitumor activity and overall was well tolerated; the safety was consistent with the reported safety profile in other tumor types.”

Learn More